Literature DB >> 29274325

HDL acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction.

Alexandre A S Soares1, Thauany M Tavoni2, Eliane C de Faria3, Alan T Remalay4, Raul C Maranhão2, Andrei C Sposito5.   

Abstract

BACKGROUND: The transport of lipids from the artery wall is one of the most essential anti-atherogenic functions of high-density lipoprotein (HDL). Recent reports of changes in the HDL composition, during myocardial infarction (MI), suggest that this function may be altered.
METHODS: Forty-one consecutive patients with ST-segment elevation MI enrolled at the Brasilia Heart Study were selected. The following HDL-related measures were determined upon admission (D1) and on the fifth day (D5) after MI: C-reactive protein, CETP and PLTP activity, HDL composition, efflux of cholesterol from J774 macrophages to HDL, and transfer of unesterified and esterified cholesterol, triglycerides and phospholipids from a donor nanoemulsion to HDL.
RESULTS: From D1 to D5, the activity of CETP decreased by 25%, but PLTP activity remained unchanged. Esterified cholesterol (-23%) and phospholipid (-9.5%) contents of HDL decreased. Transfer of triglycerides (-36.5%) and esterified cholesterol (-14.7%) to HDL from nanoemulsions was reduced, but other lipids transfers were unchanged. Cholesterol efflux to HDL was also diminished by 8.5% (p=0.04) on D5 compared to D1. It was more pronounced in patients above the 75th percentile of C-reactive protein.
CONCLUSIONS: After an MI, a simultaneous decrease in lipid transfer to HDL and in the capacity of HDL to efflux cholesterol from cells occurs. Thus, HDL with inferior atheroprotective properties may be generated in the acute post-MI period.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  High density lipoprotein; Lipid transfer; Myocardial infarction

Mesh:

Substances:

Year:  2017        PMID: 29274325     DOI: 10.1016/j.cca.2017.12.031

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  6 in total

Review 1.  Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity.

Authors:  Bronwyn A Kingwell; Stephen J Nicholls; Elena Velkoska; Svetlana A Didichenko; Danielle Duffy; Serge Korjian; C Michael Gibson
Journal:  J Am Heart Assoc       Date:  2022-04-12       Impact factor: 6.106

2.  Androgen deprivation therapy improves the in vitro capacity of high-density lipoprotein (HDL) to receive cholesterol and other lipids in patients with prostate carcinoma.

Authors:  Cicero P Albuquerque; Fatima R Freitas; Ana Elisa M Martinelli; Josefa H Lima; Rafael F Coelho; Carlos V Serrano; Willian C Nahas; Roberto Kalil Filho; Raul C Maranhão
Journal:  Lipids Health Dis       Date:  2020-06-10       Impact factor: 3.876

3.  Apolipoprotein A1 is associated with SYNTAX score in patients with a non-ST segment elevation myocardial infarction.

Authors:  Bang-Dang Chen; Xiao-Cui Chen; Yi-Ning Yang; Xiao-Ming Gao; Xiang Ma; Ying Huang; Xiao-Mei Li; Min-Tao Gai; Fen Liu; Shuo Pan; Yi-Tong Ma
Journal:  Lipids Health Dis       Date:  2019-08-07       Impact factor: 3.876

4.  Clinical characteristics of cardiovascular patients with extremely low levels of high-density lipoprotein cholesterol.

Authors:  Lufan Sun; Lian Duan; Dalin Jia
Journal:  Lipids Health Dis       Date:  2021-10-30       Impact factor: 3.876

5.  HDL-C to hsCRP ratio is associated with left ventricular diastolic function in absence of significant coronary atherosclerosis.

Authors:  Lufan Sun; Xiaorui Liu; Wenna Li; Dalin Jia
Journal:  Lipids Health Dis       Date:  2019-12-12       Impact factor: 3.876

6.  Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.

Authors:  Bo Zheng; Danielle Duffy; Pierluigi Tricoci; Helen Kastrissios; Marc Pfister; Samuel D Wright; Andreas Gille; Michael A Tortorici
Journal:  Br J Clin Pharmacol       Date:  2020-12-23       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.